HCV / Hepatitis

Study highlighting the first documented case of C auris moving from adult to pediatric unit in Maryland, COVID-19 physical health problems lingering 1 year after their hospital stay, 5-in-1 meningococcal vaccine given FDA PDUFA, and more this week from Contagion.

Please join advocates for prevention to celebrate the miracles the liver performs in maintaining the bodies’ systems, and ways to increase education to the public about the organ.

An analysis of NHANES data looked at HCV infection and risk of prostate cancer, and found contrary evidence from previous research.

Current progress of WHO's strategies to enhance global health outcomes through improved diagnosis and treatment of viral hepatitis.

Study evaluates the outcomes of orthotopic liver transplantation of HIV-HBV coinfected patients.

Study shows GBP1 assists HCV in the replication and spread against antiviral expectations.

Alcohol Awareness Month highlights the need for action amidst the alcohol crisis in the US.

Clinicians discuss screening and treatment approaches for the disease.

Insights from a CDC study on challenges and research direction in pediatric hepatitis.

Bulevirtide's key role in blocking hepatitis virus entry.

Insights on Sofosbuvir levels in pregnant women.

The evolution of treatment for hepatitis C virus during the past 15 years has been astounding, and we now are able to talk about how HCV could be eliminated.

Here is a review of an opportunistic treatment approach to HCV infection in this patient population in a European study and some of the potential challenges in applying it in the United States.

Wireless test kit transforms screening efforts towards combating the virus.

New analysis indicates that children treated at 3 years of age for perinatally acquired HCV will live longer, with less liver morbidity and lower health care costs than if treated at 6 years of age.

A vaccine targeting chronic HBV has entered its first human trial; Saskia Popescu, PhD, on the importance of pandemic preparedness and global health security; a successful phase 2 trial for a C diff treatment leads to the next phase; and more stories this week from Contagion.

This year at the Conference on Retroviruses and Opportunistic Infections (CROI), Lenacapavir shows virological suppression, Remdesivir reduces long covid risks, Bulevirtide benefits chronic HBV, HIV treatment enhances outcomes, vaginal ring or oral pre-exposure prophylaxis safe for HIV prevention throughout pregnancy.

Vaccine designed to confront chronic HBV entering its first human clinical trial.

Insights from CROI on the HepB-CpG vaccine trial.

Insights from phase 3 study evaluating bulevirtide efficacy in coinfections.

Study presented at CROI 2024 reveals chronic hepatitis B virus (HBV) infection heightens COVID-19 severity as vaccination reduces mortality and ICU demands in co-infected individuals.

In thinking about the international and national public health campaigns to eliminate hepatitis, is general awareness of the disease enough to motivate treatment-hesitant hepatitis patients to accept clinical care, or does there need to be a greater commitment beyond that?

This week, why measles and vibrio vulnificus infections are seeing outbreaks and increases in incidence rates; a medical association recommends fecal microbiota-based therapies for recurrent or severe C difficile; and an antiviral reduced a median time-to-symptom resolution.

Study exposes the adherence gap in HCV direct-acting antiviral therapy among people who inject drugs.

Shortage in hepatitis b virus (HBV) clinical trials within the WHO African region.

The federal government is working to provide greater access to testing and treatment.

Accessibility to direct-acting antivirals affecting low and middle-income countries.

Results highlight the benefit of achieving sustained virological response with DAAs for decreasing patients’ risk of carotid atherosclerosis and peripheral artery disease, especially among those with severe fibrosis.

Study reveals HEV adaptation during treatment.

GSK’s bepirovirsen received this designation, and the company has its sights on the therapy potentially providing a functional cure for the millions of people around the world who are affected by this form of viral hepatitis.